2018-19 quadrivalent inactivated influenza vaccine: A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
Study summary
Each winter, viruses belonging to two kinds of influenza A ("A/H1N1" \& "A/H3N2") and two kinds of influenza B ("B/Yamagata" \& "B/Victoria") can cause illness. Historically, the yearly influenza vaccine that was recommended in children was designed to protect against both kinds of influenza A but only one kind of influenza B. In a series of trials conducted between 2008-09 and 2010-11 (TITRE I, II, and IIB), the TITRE investigators measured antibody response to influenza B in children who were primed with two doses of trivalent inactivated influenza vaccine (TIV) containing B/Yamagata. Overall, the investigators found that 2 doses of vaccine containing B/Yamagata did not adequately prime children for response to the alternate B/Victoria antigen and that subsequent vaccine doses containing B/Victoria-lineage antigen strongly boosted antibodies to the B/Yamagata antigen that was introduced during first immunization priming, but with lower responses to B/Victoria.
For the first time since 2009-10, the recommended B/Victoria component of the seasonal influenza vaccine has been changed, from B/Brisbane/60/2008 to B/Colorado/60/2007 for the coming 2018-19 season. The investigators thus have a unique opportunity to clarify lineage-specific influenza B responses in a well-characterized cohort of children originally primed to Yamagata. The investigators' main interest is to assess whether TITRE I children primed with two doses of B/Yamagata in 2008-09 have since or are now capable of achieving a sufficient antibody response to B/Victoria following a single dose of 2018-19 QIV, ten years after their initial TIV B/Yamagata priming exposure.
Eligibility
Sex
ALL
Min age
10 Years
Max age
13 Years
Healthy volunteers
No
Inclusion Criteria:
* Child previously completed the TITRE I study in British Columbia or Quebec;
* Child is healthy (stable chronic conditions acceptable) as established by health assessment interview and verbal history-directed health examination;
* Child is available and can complete all relevant procedures during the study period;
* Parent or legal guardian is available and can be reached by phone during the study period;
* Parent/guardian provides written informed consent;
* Parent/guardian is fluent in English/French
Exclusion Criteria:
* Child has already received the 2018-19 seasonal (TIV or QIV) influenza vaccine;
* Child has a bleeding condition that would prevent vaccine injection or blood collection;
* Child has known or suspected immunodeficiency;
* Child has a suspected or known anaphylactic reaction to any of the vaccine components used in this study;
* Child has a health condition which, in the opinion of the investigator, would interfere with the evaluation or pose a health risk to the child;
* Child has received immune globulin or other blood products within the prior six weeks;
* Child has received injected or oral steroids within the prior six weeks defined by more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone \>0.5mL/kg/day or intravenous glucocorticoid steroid). Nasal, topical or inhaled steroids are allowed;
* Child has received any live vaccine within 28 days of the study vaccine or is scheduled to receive live vaccine during the study period;
* Child has received any inactivated vaccine within 14 days of the study vaccine;
* Child is or will be enrolled in any other clinical trial of a drug, vaccine or medical device during the study period.
Primary outcome measure(s)
Seroprotection rate (SPR) for B/Victoria vaccine strains — Pre-vaccination SPR based on hemagglutination inhibition (HI) assay for current (B/Colorado/06/2017-like) and prior (B/Brisbane/60/2008-like) Victoria lineage vaccine strains
Seroprotection rate (SPR) for B/Victoria vaccine strains — 4-6 weeks after receipt of QIV SPR based on hemagglutination inhibition (HI) assay for current (B/Colorado/06/2017-like) and prior (B/Brisbane/60/2008-like) Victoria lineage vaccine strains
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.